Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that causes severe disease following congenital infection and in immunocompromised individuals. No vaccines are licensed, and there are limited treatment options. We now show that the addition of anti-HCMV antibodies (Abs) can activate NK cells prior to the production of new virions, through Ab-dependent cellular cytotoxicity (ADCC), overcoming viral immune evasins. Quantitative proteomics defined the most abundant HCMV proteins on the cell surface, and we screened these targets to identify the viral antigens responsible for activating ADCC. Surprisingly, these were not structural glycoproteins; instead, the immune evasins US28, RL11, UL5, UL141, and UL16 each individually primed ADCC. We isolated human monoclonal Abs (mAbs) specific for UL16 or UL141 from a seropositive donor and optimized them for ADCC. Cloned Abs targeting a single antigen (UL141) were sufficient to mediate ADCC against HCMV-infected cells, even at low concentrations. Collectively, these findings validated an unbiased methodological approach to the identification of immunodominant viral antigens, providing a pathway toward an immunotherapeutic strategy against HCMV and potentially other pathogens.

Highlights

  • Human cytomegalovirus (HCMV) establishes lifelong infection in the face of robust humoral and cell-mediated immune responses

  • We examined the ability of Cytotect to enhance NK cell activation in the presence of target cells infected with a HCMV strain (Merlin) expressing the complete repertoire of virally encoded immune evasins

  • Since adaptive NK cells are the primary mediators of Ab-dependent cellular cytotoxicity (ADCC) in PBMCs from HCMV-seropositive donors [29, 35,36,37,38], we examined the activation of CD56+ NK cells in the CD57+ and NKG2C+ subsets, measuring degranulation via surface mobilization of CD107a

Read more

Summary

Introduction

Human cytomegalovirus (HCMV) establishes lifelong infection in the face of robust humoral and cell-mediated immune responses. A vaccine against HCMV is considered to be the highest priority, for the prevention of congenital disease [1], but none has been licensed. Antibody (Ab) responses have been investigated as a basis for improved vaccines and immunotherapies [3,4,5,6,7,8,9]. Several lines of evidence support a protective role for Abs in infection, including observational studies of natural immunity, which have documented a correlation between Ab titers and the prevention of intrauterine transmission [10,11,12,13].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call